OPPILOTECH, LTD.   London, UK
oppilotech.com

OPPILOTECH:CARB-X
TARGETS SYNTHESIS OF LPS

Indirect Therapeutics
Oppilotech is focused on the development of safe antibacterial compounds against drug resistant organisms. This approach entails developing potentiators – agents that can permeabilize the cell envelope allowing the use of established antibacterial compounds. To develop potentiators, Oppilotech has built the most detailed, accurate, computational network model of bacterial cell envelope (LPS, peptidoglycan & phospholipids components) biogenesis that has ever been assembled. The model has allowed Oppilotech to identify a protein involved in the synthesis of LPS found in Gram-negative bacteria that has unique features making it an excellent viable target for drug development. The CARB-X funding allows Oppilotech to undertake early stage experimental analysis of agents that can modulate this target to disrupt the envelope.

Current Development Stage: Hit to Lead

CARB-X Investment: Investment of up to $0.12m

Initial CARB-X Investment Date: April 1, 2017

Graduation Date: October 31, 2017